Shares to buy today: Investack looks at about 20% of Side Late in UltraTech Cements; What should investors do now?

Some brokerage companies have recently shared a positive look at leading companies, with potential growth opportunities and strategic progresses for the next 12 months.

Investack, Jefferies and Nuwama have maintained ‘bye’ ratings on UltraTech Cement, Apollo Hospitals and Crompton Greens Consumer Electricals Limited, a strong sidewalk for each stock.

We have collected a list of recommendations for top brokerage companies of ETNO and other sources:

Investack on UltraTech Cement: Buy | Target Rs. 12,450 | LTP RS 10420 | About 20% of Side Ltd

Investack maintained a ‘buy’ rating on ultrake cement with a target price of Rs 12,450, which suggests about 20% of the last trade price of Rs 10,420.

According to Investack, the market has been overturned on the access to the wire and cable segment of the ultrate.

They believe that the segment offers about 4 times healthy assets and EBIT margins ranging from 8% to 10%, making recent stock correction uncontrollable. However, they have noted that the main risk of viewing is the diversity in the company’s unrelated category.

Despite this, the Investack is positive on ultra -cement probability and maintains a ‘bye’ recommendation at 12,450, with the target price set.

Also Read: 21% Ka Zatka: UltraTech Entry Jolts Cable and Wire Companies, Profit on Line

Jefferies at Apollo Hospitals: Buy | Target Rs. 7,900 | LTP RS6187 | Side Ltd 27%

Jefferies maintained a ‘buy’ rating at Apollo hospitals with a target price of Rs 7,900, which shows its last commercial price from 6,187 to 27%.

Among the additions of new beds, the main debate is around the durability of the average income of the bed (ARPOB) for Apollo.

However, Jefferies believe that concerns on ARPOB are uncontrolled, as bed additions for organized players are about 2% of their current capacity.

These additions are expected to be phased in 3 to 5 years, which reduces the immediate impact on ARPOB growth.

Significantly, Apollo hospitals maintained the annual growth rate (CAGR) of 8.3% ARPOB compound annual growth rate (CAGR), despite facing multiple headwinds during this period.

Based on these factors, Jefferies remain positive at Apollo hospitals and maintains a ‘buy’ recommendation with a target price of Rs 7,900.

Crompton Greenses Consumer Electricals Ltd. Nuvama: Buy | Target Rs. 500 | LTP RS324 | Side Ltd 54%

Nuvama has paid Rs. Maintains a ‘buy’ rating with a target price of 500, which has its last Rs. The last trade price of 324 indicates a potential side of 54%.

The company has repeated that it is progressing well on its Crompton 2.0 strategy, which focuses on achieving industry-generated profit after tax (PAT), stabilizing its position in the lighting market, and turning butterfly Gandhi devices.

In addition, Crompton is intended to get a large part of the premium fans market. The next bee is likely to provide more market share gain opportunities for the next bee 2.0 transition company in January 2026.

Crompton has also made a positive start in the summer season tu. Moreover, the company is searching for three to four new categories in solar pumps, and the restructuring of the butterfly Gandhi is completed with a new team, aiming for the development of mid-teenagers.

Based on this strategic move and growth prospects, the newwama is optimistic about the future operations of Crompton and maintains a ‘buy’ recommendation with a target price of Rs.500.

(Connection: The recommendations, suggestions, views and views of the experts are their own. This does not represent opinions of economic time)